Concert Genetics Earns Patent for Innovative Methods of Automating Genetic Test Coverage and Payment Accuracy
Concert links 160,000 genetic tests to coverage criteria, automates accurate payment, and supports high-value clinical test ordering
News provided by
Share this article
Share this article
NASHVILLE, Tenn., June 9, 2021 /PRNewswire/ The U.S. Patent and Trademark Office has issued Concert Genetics patent
US10,896,405B1 for innovative methods that enable real-time coverage determination and accurate reimbursement of genetic tests, the company announced today.
As the patent describes, Concert s system converts health plan medical policies, typically text documents, into machine-readable criteria, and then links the criteria to every genetic test on the market. This system leverages Concert s platform for collecting, standardizing and organizing genetic test information, represented in patent
TN-RDAC To Inform TennCARE On Pharmaceutical Treatments Wednesday, May 12, 2021 The newly formed Tennessee Rare Disease Advisory Council or TN-RDAC (pronounced AHR-dak) has set its priorities to advocate for Tennesseans diagnosed with rare diseases, including advising TennCare’s Pharmacy Advisory Committee and Drug Utilization Review Committee on pharmaceutical treatments, as well as identifying the overall impact of rare diseases on Tennesseans. Created by public charter in the 111th Tennessee General Assembly, TN-RDAC elected at its inaugural meeting its Chairman Dr. Scott Strome, executive dean of the University of Tennessee College of Medicine and vice chancellor for clinical affairs at UT Health Science Center. Dr. Strome brings rare disease research and clinical experience to the TN-RDAC.
Gene Amplification Market Segmentation, Parameters and Prospects 2021 to 2027 Market Research Report sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.